Moderna developing mRNA vaccine for Lyme disease


A Lyme disease vaccine could be on its way soon, according to pharmaceutical company Moderna.
The company has announced two new mRNA vaccines in development that could prevent Lyme disease, marking the "first application of its mRNA technology to bacterial pathogens." The technology was used in creating the COVID-19 vaccine. Moderna also announced vaccine development plans for norovirus and RSV, which have both been spreading rapidly.
"Untreated, Lyme disease can be very serious," emergency physician and George Washington University professor Leana Wen told Axios. "Some people develop debilitating symptoms that really impact their lives." The disease comes from tick bites and can cause fever, chills, joint pain, and rashes, according to the Centers for Disease Control. If left untreated, the symptoms can be more severe including heart palpitations, arthritis, and facial palsy.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There has only been one human Lyme disease vaccine that was ever available on the market and it was pulled in 2002 because "negative press coverage and limited awareness of the benefits of the vaccine decreased consumer demand for the vaccine," according to a 2007 study. However, there are approximately 120,000 reported cases of Lyme reported each year in the U.S. and Europe, and that number is rising due to climate change, per Axios.
Pfizer and its partner company Valneva also have a Lyme disease vaccine in the works that has shown promise, with the company saying it could get approved as early as 2025. It is still good practice to wear long sleeves and use insect repellant to prevent tick bites in the first place, but "after years of relying on such preventive steps, an age of advanced drugs and vaccines could be nigh," Axios writes.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
The First Homosexuals: The Birth of a New Identity, 1869–1939
Feature Wrightwood 659, Chicago, through Aug. 2
-
Why the FDA wants to restrict kratom-related products
In the Spotlight The compound is currently sold across the United States
-
Israeli NGOs have started referring to Gaza as a 'genocide' — will it matter?
TODAY'S BIG QUESTION For the first time since fighting began in 2023, two Israeli rights groups have described their country's actions in the Gaza Strip as 'genocide' while famine threatens the blockaded Palestinian territory
-
Scientists are developing artificial blood for use in emergencies
Under the radar It could aid in global blood shortages
-
Babies born using 3 people's DNA lack hereditary disease
Under the Radar The method could eliminate mutations for future generations
-
Not just a number: how aging rates vary by country
The explainer Inequality is a key factor
-
Children's health has declined in the US
The Explainer It's likely a sign of larger systemic issues
-
Cytomegalovirus can cause permanent birth defects
The Explainer The virus can show no symptoms in adults
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Climate change can impact our gut health
Under the radar The gastrointestinal system is being gutted